Old and new blood markers in human colorectal cancer

JL Wautier, MP Wautier - International Journal of Molecular Sciences, 2022 - mdpi.com
Cancer is a predominant cause of mortality all over the world. Lung, prostate, and colorectal
cancer are the more frequent in men while breast and colorectal have a high incidence in …

Realizing the promise of project optimus: challenges and emerging opportunities for dose optimization in oncology drug development

W Gao, J Liu, B Shtylla… - CPT …, 2024 - Wiley Online Library
Project Optimus is a US Food and Drug Administration Oncology Center of Excellence
initiative aimed at reforming the dose selection and optimization paradigm in oncology drug …

Essential updates 2020/2021: Advancing precision medicine for comprehensive rectal cancer treatment

I Takemasa, A Hamabe, M Miyo… - Annals of …, 2023 - Wiley Online Library
In the paradigm shift related to rectal cancer treatment, we have to understand a variety of
new emerging topics to provide appropriate treatment for individual patients as precision …

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (CtDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)

S Chakrabarti, AK Kasi, AR Parikh, A Mahipal - Cancers, 2022 - mdpi.com
Simple Summary After the surgical removal of colorectal cancer (CRC), residual cancer cells
undetectable by standard blood tests and imaging studies are responsible for cancer …

Beyond population‐level targets for drug concentrations: precision dosing needs individual‐level targets that include superior biomarkers of drug responses

TM Polasek, RW Peck - Clinical Pharmacology & Therapeutics, 2024 - Wiley Online Library
The purpose of precision dosing is to increase the chances of therapeutic success in
individual patients. This is achieved in practice by adjusting doses to reach precision dosing …

Harnessing minimal residual disease as a predictor for colorectal cancer: Promising horizons amidst challenges

X Wen, D Coradduzza, J Shen, AM Scanu, MR Muroni… - Medicina, 2023 - mdpi.com
Minimal Residual Disease (MRD) detection has emerged as an independent factor in
clinical and pathological cancer assessment offering a highly effective method for predicting …

Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with …

R Raj, CJ Wehrle, N Aykun, H Stitzel, WW Ma… - Cancers, 2023 - mdpi.com
Simple Summary Immunotherapy is emerging as an improved systemic treatment for select
patients with advanced unresectable hepatocellular carcinoma. An objective response is …

[HTML][HTML] Utilizing plasma circulating tumor DNA sequencing for precision medicine in the management of solid cancers

Y Cha, S Kim, SW Han - Cancer Research and Treatment …, 2023 - synapse.koreamed.org
Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor
molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is …

[HTML][HTML] Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by …

C Nawaf, A Shiang, PS Chauhan, AA Chaudhuri… - Translational …, 2023 - Elsevier
Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed
method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has …

Role of circulating tumor DNA among patients with colorectal peritoneal metastases

JM Baumgartner, GP Botta - Journal of Gastrointestinal Cancer, 2024 - Springer
Purpose This was a review of circulating tumor DNA (ctDNA) in patients with peritoneal
metastases from colorectal cancer. Methods We searched the PubMed database for studies …